Tocilizumab and COVID-19: Timing of administration assessment

Recent evidence showed greater efficacy of tocilizumab (TCZ) in the subgroups of COVID-19 patients who presented with symptoms for less than 7 days and in those only receiving oxygen. We retrospectively analyzed a compassionate use cohort to determine the best timing for TCZ injection. We showed no...

Descripción completa

Detalles Bibliográficos
Autores principales: Richier, Q., Jachiet, V., Bonnemains, V., Plaçais, L., Abisror, N., Garnier, M., Pacanowski, J., Dhote, R., Hinchschberger, O., Michel, M., Bienvenu, B., Comarmond, C., Lacombe, K., Mekinian, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239201/
https://www.ncbi.nlm.nih.gov/pubmed/34198000
http://dx.doi.org/10.1016/j.idnow.2021.06.304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239201/
https://www.ncbi.nlm.nih.gov/pubmed/34198000
http://dx.doi.org/10.1016/j.idnow.2021.06.304

Ejemplares similares